Bloomberg News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eric Pfanner
Martin Marietta to buy Lhoist unit in $13.5 billion deal
; ; More for You ; ; ; ; Continue reading More for You
Martin Marietta to buy Lhoist unit in $13.5 billion deal
; ; More for You Continue reading More for You
Martin Marietta to Buy Lhoist Unit in $13.5 Billion Deal Original
Photographer: Samuel Corum/Bloomberg (Bloomberg) -- Martin Marietta Materials Inc. agreed to combine with building materials supplier Lhoist North America in a transaction valued at $13.5 billion, including debt.
Frasers makes US$2.3 bil offer to buy rest of Hugo Boss
Sonja Wind & Eric Pfanner / BloombergThu, Jun 11, 2026 • 04:45 PM GMT+08 • • 4 min read Mike Ashley has made a cash bid of €38 a share for the German label known for its premium-priced suits, casual attire and underwear. Follow us on Facebook and join our Telegram channel for the latest updates.
Hugo Boss: Großaktionär Frasers macht Offerte für alle Aktien – nur 4% Aufschlag
June 11, 2026 at 5:27 AM UTC Hugo Boss hat ein Übernahmeangebot des britischen Einzelhändlers Frasers Group erhalten. Der bereits mit rund 26% beteiligte Großaktionär bietet rund 2 Milliarden Euro für die ausstehenden Anteile des deutschen Konzerns.
Ashley’s Frasers seeks to buy rest of Boss for $2.3 billion
; ; Continue reading More for You Continue reading More for You
Frasers Makes $2.3 Billion Offer to Buy Rest of Hugo Boss
Bloomberg (Bloomberg) -- Frasers Group Plc offered to buy the rest of Hugo Boss AG for about €2 billion ($2.3 billion) as billionaire Mike Ashley seeks to add another fashion brand to his growing collection.
Smiths Sells Airport Scanner Unit to CVC at £2 Billion Value
(Bloomberg) -- Smiths Group Plc agreed to sell its unit that makes airport security scanners to private equity firm CVC Capital Partners at an enterprise valuation of £2 billion ($2.7 billion).
Após perder disputa pela Metsera, Novo quer avançar em drogas para obesidade e ir além
Bloomberg — O CEO da Novo Nordisk, Mike Doustdar, pode ter perdido para a Pfizer em uma batalha de aquisição de US$ 10 bilhões da desenvolvedora de medicamentos para obesidade Metsera, mas não se espera que ele desista de fazer negócios tão cedo. A empresa dinamarquesa busca recuperar o terreno perdido no mercado em expansão de perda de peso.
Izvršni direktor Novoa traži nove prilike nakon poraza Metsera od Pfizera
Izvršni direktor tvrtke Novo Nordisk, Mike Doustdar, izgubio je u borbi vrijednoj 10 milijardi dolara za preuzimanje tvrtke Metsera, koja razvija lijekove protiv pretilosti, od konkurenta Pfizera. No, ne očekuje se da će odustati od akvizicija dok kompanija nastoji vratiti izgubljenu poziciju na tržištu lijekova za mršavljenje koje bilježi snažan rast.
Izvršni direktor Novoa okreće se novim ciljevima nakon što je izgubio Metseru od Pfizera
Izvršni direktor tvrtke Novo Nordisk, Mike Doustdar, izgubio je u borbi vrijednoj 10 milijardi dolara za preuzimanje tvrtke Metsera, koja razvija lijekove protiv pretilosti, od konkurenta Pfizera. No, ne očekuje se da će odustati od akvizicija dok kompanija nastoji vratiti izgubljenu poziciju na tržištu lijekova za mršavljenje koje bilježi snažan rast.
Izvršni direktor Novo Nordiska se po neuspehu usmerja v nove cilje
Izvršni direktor podjetja Novo Nordisk, Mike Doustdar, je morda izgubil proti podjetju Pfizer v 10 milijard dolarjev vrednem prevzemu razvijalca zdravil za debelost, podjetja Metsera. Vendar ne pričakujte, da bo kmalu obupal nad sklepanjem poslov, saj si danska družba prizadeva povrniti izgubljeni položaj na cvetočem trgu izdelkov za hujšanje.
Novo’s CEO Turns to Next Targets After Losing Metsera to Pfizer
Chief Executive Officer may have lost out to in a $10 billion takeover for obesity drug developer But don’t expect him to give up on dealmaking any time soon as the Danish company seeks to regain lost ground in the booming weight-loss market. Novo, the owner of Wegovy and Ozempic, will continue to look at opportunities in obesity, diabetes and their associated comorbidities, according to people familiar with the situation.
Novo’s CEO Turns to Next Targets After Losing Metsera to Pfizer
Novo CEO Mike Doustdar in the Oval Office of the White House, on Nov. 6. (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for obesity drug developer Metsera Inc.
Novo’s CEO Turns to Next Targets After Losing Metsera to Pfizer
Chief Executive Officer may have lost out to in a $10 billion takeover for obesity drug developer But don’t expect him to give up on dealmaking any time soon as the Danish company seeks to regain lost ground in the booming weight-loss market. Novo, the owner of Wegovy and Ozempic, will continue to look at opportunities in obesity, diabetes and their associated comorbidities, according to people familiar with the situation.
Kimberly-Clark to Buy Tylenol Owner Kenvue in $40 Billion Deal
agreed to buy in a cash and stock deal that gives the consumer-health company that owns brands like Tylenol for about $40 billion. Kenvue holders will get $3.50 per share in cash and 0.14625 Kimberly-Clark shares per Kenvue share, according to a statement Monday, for a total consideration of $21.01 a share based on Kimberly-Clark’s Friday closing price. Kenvue closed at $14.37 on Friday. The deal has an enterprise value of about $48.7 billion, the companies said.
GSK CEO Walmsley to Exit After Struggling to Win Over Investors
Emma Walmsley Photographer: Jaimi Joy/Bloomberg (Bloomberg) -- GSK Plc Chief Executive Officer Emma Walmsley is stepping down after almost nine years in which she struggled to win investor backing and will be succeeded by the British drugmaker’s...
Porsche and VW Lower Forecasts Due to Pullback From EVs (2)
and its parent cut their outlook for the year, citing the sports-car maker taking a €1.8 billion ($2.2 billion) hit to operating profit linked to pushing back the introduction of new electric vehicles. Porsche now forecasts an operating return on sales of no more than 2%, down from a previous range of 5% to 7%, for 2025. It’s the fourth time the 911 maker has lowered guidance this year. The American depositary receipts fell 6.4%. The company announced a number of delays to its EV plans.
Porsche, VW Lower 2025 Forecasts Because of Pullback From EVs
Business Technology Equipment Fuel Porsche Now Predicts an Operating Return on Sales of No More Than 2%; Volkswagen's Estimate Is 2%-3% An automobile sculpture outside the Porsche AG Zuffenhausen plant in Stuttgart, Germany.
ポルシェ、4回目の通期業績見通し下方修正－EV投入の遅れ響く
ドイツの高級スポーツカーメーカー、ポルシェと親会社のフォルクスワーゲン（VW）が通期業績見通しを下方修正した。新型電気自動車（EV）の投入延期に関連し、ポルシェの営業利益は18億ユーロ（約3100億円）押し下げられると説明した。 これによりポルシェの通期売上高営業利益率は2%弱となる見通し。従来は5－7%と見込まれていた。同社が今年の通期見通しを下方修正するのは4回目。この発表を受け、同社の米国預託証券（ADR）は一時6.4％下落した。 ポルシェはEV計画で遅れが続いている。「カイエン」の上に位置づけられ、EVのみの展開を予定していたスポーツ用多目的車（SUV）の新モデルも、当初はEVでなく、内燃機関車とハイブリッド車とする方針を明らかにした。 今年に入り複数の経営幹部を交代させたポルシェは、内燃機関車とプラグインハイブリッドのモデル追加や、人員カットを含むコスト削減で業績を回復させようとしている。自前でバッテリーを製造する計画もあったが、EV需要の低迷で断念した。...
Porsche and VW Lower Forecasts Due to Pullback From EVs
An automobile sculpture outside the Porsche AG Zuffenhausen plant in Stuttgart, Germany.
Porsche Cuts Outlook and Sees €1.8 Billion Hit From EV Pullback
cut its outlook for the year, saying it expects to take a €1.8 billion ($2.2 billion) hit to operating profit as it pushes back the introduction of new electric vehicles and sticks with internal combustion engines and hybrid drivetrains for longer. The German sports-car maker now forecasts a return on sales of as much as 2%, down from a previous range of 5% to 7%, for the 2025 financial year. The American depositary receipts fell 3.3%.
Porsche Cuts Outlook and Sees €1.8 Billion Hit From EV Pullback
Meta CTO explains why the smart glasses demos failed at Meta Connect — and it wasn’t the Wi-Fi Meta chief technology officer Andrew Bosworth took to his Instagram to explain, in more technical detail, why multiple demos of Meta’s new smart-glasses technology failed at Meta Connect, the company’s developer conference, this week. Meta on Wednesday introduced three new pairs of smart glasses, …
Lowe's to Buy Foundation Building in $8.8 Billion Cash Deal
Article content (Bloomberg) — Lowe’s Cos. agreed to buy Foundation Building Materials for about $8.8 billion in cash as it expands further beyond home-improvement supplies to serve more professional customers. Sign In or Create an Account Article content Foundation Building, a North American distributor of drywall and other building products, has a network of over 370 locations in the US and Canada and had about $6.5 billion in sales last year, according to a statement Wednesday.
Lowe’s to Buy Foundation Building in $8.8 Billion Cash Deal
agreed to buy , a North American distributor of drywall and other building products, for about $8.8 billion in cash. The deal expands Lowe’s operations further beyond home-improvement supplies to serve more professional customers. Foundation Building was acquired by private equity firm in a deal announced in November 2020. Foundation Building Materials has a network of over 370 locations in the US and Canada and had about $6.5 billion in sales last year, according to a statement.
Relojes suizos, bajo presión: EE.UU. impone uno de los aranceles más altos del mundo
Bloomberg — Los exportadores suizos, desde fabricantes de relojes a empresas farmacéuticas, se preparan para las consecuencias financieras de los aranceles del 39% impuestos por el presidente estadounidense Donald Trump, uno de los más elevados a nivel mundial en su creciente guerra comercial.
Trump unleashes massive tariffs on Swiss watches, pharma firms
BUSINESS Eric Pfanner and Katie Linsell Bloomberg View Comments Switzerland’s exporters, from watch makers to pharmaceutical companies, are bracing for the financial fallout from US President Donald Trump’s 39% tariffs, one of the steepest rates globally in his escalating trade war. The levies slapped on Switzerland are part of a slew of new tariffs unveiled by Trump late Thursday as the US president forges ahead with his effort to reshape international commerce.
Trump-Zölle: Schweizer Uhren- und Pharmaunternehmen besonders betroffen
Die Schweizer Exportwirtschaft – von Uhren über Pharma bis zu Medizintechnik – muss sich auf die wirtschaftlichen Folgen der von US-Präsident Donald Trump verhängten Strafzölle in Höhe von 39% einstellen.
Akcije satova u padu zbog carina - Rolex bi mogao poskupeti i za dvadeset odsto
Akcije kompanije Watches of Switzerland Group Plc pale su za čak šest odsto nakon što je predsednik SAD Donald Trump uveo carinu od 39 odsto na uvoz iz Švajcarske – jednu od najviših stopa na svetu u okviru njegove eskalirajuće trgovinske politike. Ovaj maloprodajni lanac, koji u Velikoj Britaniji i SAD prodaje brendove poput Rolexa i drugih švajcarskih satova, direktno je pogođen novim talasom carinskih mera.
Поради Трамп остар пад на акциите на швајцарските компании за часовници | Bloomberg Adria
Цените на акциите на групацијата „ВОС“ (Watches of Switzerland Group Plc) паднаа за дури 6 отсто откако американскиот претседател Доналд Трамп воведе царина од 39 отсто за увозот од Швајцарија, една од највисоките стапки на глобално ниво во неговата ескалација на трговската војна. Оваа компанија која тргува на мало продава ролекс („Rolex“) и други швајцарски часовници во Велика Британија и САД. Сега излегува дека ќе понесе силен товар на најновиот царински напад.
Trumpove carine spodnesle tla delnici Watches of Switzerland
Delnice podjetja Watches of Switzerland Group so se pocenile za kar šest odstotkov, potem ko je ameriški predsednik Donald Trump uvedel 39-odstotno carino na uvoz iz Švice – eno najvišjih carin na svetu v okviru njegove vse bolj zaostrene trgovinske vojne. Vaše prijave ni bilo mogoče shraniti. Prosimo, poskusite ponovno. Uspešno ste se prijavili.
Trumpove carine spodnesle tla delnici, ure Rolex za petino dražje?
Delnice podjetja Watches of Switzerland Group so se pocenile za več kot šest odstotkov, potem ko je ameriški predsednik Donald Trump uvedel 39-odstotno carino na uvoz iz Švice – eno najvišjih carin na svetu v okviru njegove vse bolj zaostrene trgovinske vojne. Vaše prijave ni bilo mogoče shraniti. Prosimo, poskusite ponovno. Uspešno ste se prijavili.
Trump Unleashes Massive Tariffs on Swiss Watches, Pharma Firms
A Watches of Switzerland Group Plc store in London.
Watches of Switzerland Tumbles After Trump’s 39% Tariff Salvo
Shares of fell as much as 6% after US President imposed a 39% tariff on imports from Switzerland, one of the steepest rates globally in his escalating trade war. The retailer, which sells Rolex and other Swiss timepieces in the UK and the US, bore the brunt of the latest tariff salvo. Financial markets in Switzerland were closed for a holiday, initially sparing listed producers such as and . Swiss watch exports had already been hit in advance of the latest news, in the spring when Trump ...
Carine srušile dionice satova - Rolex bi mogao poskupjeti za dvadeset posto
Dionice tvrtke Watches of Switzerland Group Plc pale su za čak šest posto nakon što je američki predsjednik Donald Trump uveo carinu od 39 posto na švicarski uvoz - jednu od najviših stopa na svijetu - kao dio svoje eskalirajuće trgovinske politike. Trgovac na malo, koji prodaje marke poput Rolexa i drugih švicarskih satova u Velikoj Britaniji i SAD-u, izravno je pogođen novim valom carinskih mjera.
Nestlé Picks Ex-Inditex Boss to Succeed Bulcke as Chairman (1)
X Your Choices Regarding Cookies and Identifiers We and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Nestlé Picks Ex-Inditex Boss to Succeed Bulcke as Chairman (1)
Nestlé SA extended its leadership overhaul by proposing longtime Inditex SA executive Pablo Isla as its next chairman to succeed company veteran Paul Bulcke when he retires next year. The move by the Swiss owner of Nespresso coffee and Purina pet food follows the surprise ouster of CEO Mark Schneider last year. His successor, Laurent Freixe, has been trying to restore sales growth as the Swiss company confronts challenges including rising costs and trade wars.
Nestlé traz veterano do setor de varejo para substituir presidente após aposentadoria
Bloomberg — A Nestlé ampliou sua reformulação da liderança ao propor Pablo Isla, executivo de longa data da Inditex, como seu próximo presidente, para suceder o veterano da empresa Paul Bulcke quando ele se aposentar no próximo ano. A medida tomada pela empresa suíça dona do café Nespresso e dos alimentos para animais de estimação Purina ocorre após a surpreendente demissão do CEO Mark Schneider no ano passado.
Nestlé Picks Ex-Inditex Boss to Succeed Bulcke as Chairman
Pablo Isla in 2024 (Bloomberg) -- Nestlé SA extended its leadership overhaul by proposing longtime Inditex SA executive Pablo Isla as its next chairman to succeed company veteran Paul Bulcke when he retires next year.
Medtronic to Split Off Diabetes Unit as Tariffs Hit Earnings (1)
Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the US-China trade dispute threatens its earnings. The unit will become a new publicly traded entity, with an initial public offering the favored route, according to a statement Wednesday. Diabetes accounted for about 8% of Medtronic’s $33.5 billion revenue in the latest fiscal year.
Medtronic to Split Off Diabetes Unit as Tariffs Hit Earnings (1)
X Your Choices Regarding Cookies and Identifiers We and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Medtronic to separate diabetes unit as tariffs hit earnings
Breadcrumb Home Digital Health May 21, 2025 09:36 AM Tweet Share Share Email More Reprints Print Getty Images Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the U.S.-China trade dispute threatens its earnings. The unit will become a new publicly traded entity, with an initial public offering the favored route, according to a statement Wednesday.
Medtronic to Split Off Diabetes Unit as Tariffs Hit Earnings
(Bloomberg) -- Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the US-China trade dispute threatens its earnings.
Pressão de concorrentes de Ozempic e Wegovy leva Novo Nordisk a demitir CEO
Bloomberg — A Novo Nordisk destituiu o CEO Lars Fruergaard Jorgensen enquanto a farmacêutica luta contra a crescente concorrência para seu tratamento de obesidade Wegovy, que tem pesado sobre o preço das ações. A empresa dinamarquesa disse que Jorgensen está saindo por acordo mútuo com o conselho, embora ele continue como chefe “por um período para apoiar uma transição suave para uma nova liderança”. A busca por um novo líder já começou, disse a empresa em um comunicado na sexta-feira (16).
Novo ousts CEO Jorgensen after Lilly competition hits shares
Novo Nordisk said Lars Fruergaard Jorgensen was leaving by mutual agreement. MADS CLAUS RASMUSSEN/Ritzau Scanpix/AFP via Getty Images
Novo Nordisk reemplazará a su CEO tras desplome de acciones y presión de Eli Lilly
Bloomberg — Novo Nordisk A/S (NVO) anunció la salida de su CEO, Lars Fruergaard Jorgensen, en medio de una creciente presión competitiva sobre su tratamiento contra la obesidad, Wegovy, que ha impactado negativamente el desempeño de las acciones. La farmacéutica danesa informó que Jorgensen dejará el cargo de mutuo acuerdo con la junta directiva, aunque permanecerá en la compañía por un tiempo para asegurar una transición fluida hacia un nuevo liderazgo.
Sanofi to Invest at Least $20 Billion in US Through 2030 (1)
Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their American operations as President Donald Trump threatens to impose tariffs and cut prices on drugs. The investments will include a “significant increase” in research and development spending and billions of dollars devoted to US manufacturing, the French drugmaker said in a statement Wednesday.
Sanofi to Invest at Least $20 Billion in US Through 2030 Original
A logo at the Sanofi SA campus in the Gentilly district of Paris, France, on Tuesday, April 25, 2023. Sanofi is due to report results on Thursday, with analysts focused on the performance of key drug Dupixent.
Mercedes Will Make Another Model in US to Counter Tariffs (3)
Mercedes-Benz Group AG plans to move production of another vehicle to the US as President Donald Trump’s tariffs raise costs and threaten to make imported cars uncompetitive. The German automaker said in a statement that it will shift assembly of a “core segment vehicle” to its factory in Tuscaloosa, Alabama, by 2027. Though Mercedes didn’t specify which model, its most popular import in that category is the GLC sport utility vehicle, which sold 64,163 units in the US last year.
Mercedes will make another model in U.S. to counter tariffs
Article content (Bloomberg) — Mercedes-Benz Group AG plans to move production of another vehicle to the U.S. as President Donald Trump’s tariffs raise costs and threaten to make imported cars uncompetitive. Sign In or Create an Account Article content Article content The German automaker said in a statement that it will shift assembly of a “core segment vehicle” to its factory in Tuscaloosa, Alabama, by 2027.
Show More
loading
Actions
Get in touch with Eric
Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack